Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Dexamethasone + Ixazomib + Selinexor|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ixazomib||Ninlaro||MLN9708||Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov)|
|Selinexor||Xpovio||KPT-330||Xpovio (selinexor) inhibits CRM1 (XPO1), preventing CRM1-mediated nuclear export of tumor suppressor proteins and potentially restoring normal tumor suppressor function (PMID: 30976603, PMID: 31793336). Xpovio (selinexor) is FDA approved for use in combination with Adexone (dexamethasone) in patients with relapsed or refractory multiple myeloma after at least four prior therapies, and in diffuse large B cell lymphoma after two or more prior therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02831686||Phase I||Dexamethasone + Ixazomib + Selinexor||A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma||Active, not recruiting|